Female Germline Stem Cells
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Stem Cells".
Deadline for manuscript submissions: closed (15 May 2019) | Viewed by 37556
Special Issue Editors
Interests: ovarian development; germline stem cells; in vitro growth; human oocyte development
Interests: female germline stem cells; mitochondria in health and disease; aging; reproductive health
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
For almost a century, there has been a debate surrounding the ability of adult female mammals to undergo post-natal germ cell renewal. In 2004, a study proposing germ cell renewal in adult female mice was published, and, since then, the isolation of mitotically active cells expressing germline markers has been reported from the ovaries of adult rodents, cows, sheep, primates, and humans. The development of these oogonial stem cells (OSCs) in vitro and the generation of live young from fully differentiated rodent OSCs has also been described.
Whilst there remains controversy over the biological significance of these cells, it must be acknowledged that the identification and isolation of populations of cells with germline potential within the adult mammalian ovary in general, and the human ovary in particular, represents a significant advance with the potential to change infertility treatments.
The aim of this Special Issue is to provide an overview of the developments in this field from expert laboratories to highlight the methodology used to isolate and characterise these cells and to place these cells in the context of our understanding of mammalian ovarian development.
Prof. Evelyn Telfer
Dr. Dori Woods
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- female germline stem cells
- oogonial stem cells
- ovarian development
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.